Efficacy of a spatial repellent for control of malaria in Indonesia: a cluster-randomized controlled trial

Din Syafruddin[1], Puji BS Asih[1], Ismail Ekoprayitno Rozi[1], Dendi Hadi Permana[1], Anggi Puspa Nur Hidayati[1], Lepa Syahrani[1], Siti Zubaidah[1], Dian Sidik[2], Michael J. Bangs[3], Claus Bøgh[4], Fang Liu[5], Evercita C. Eugenio[5], Jared Hendrickson[6], Timothy Burton[7], J. Kevin Baird[8], Frank Collins[7], John P. Grieco[7], Neil F. Lobo[7±] and Nicole L. Achee[7±*]

[1]Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia;

[2]Department of Epidemiology, Faculty of Public Health, Universitas Hasanuddin, Makassar, Indonesia

[3]Public Health and Malaria Control, PT Freeport Indonesia, International SOS, Kuala Kencana, Papua Indonesia;

[4]The Sumba Foundation, Public Health and Malaria Control, Bali, Indonesia;

[5]Department of Applied Mathematics, University of Notre Dame, Indiana;

[6]Center for Computer Research, University of Notre Dame, Notre Dame, Indiana;

[7]Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana;

[8]Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, and the Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom;

[±]Indicates equal seniority

*Corresponding author:

Nicole L. Achee, PhD
Research Professor
Eck Institute for Global Health
Department of Biological Sciences
239 Galvin Life Science Center
Notre Dame, Indiana 46556
Ph: 574.631.1561
Email: nachee@nd.edu

38 ***Abstract.*** A cluster randomized, double-blinded, placebo-controlled trial was conducted to
39 estimate protective efficacy of a spatial repellent against malaria infection at Sumba, Indonesia.
40 Following radical cure in 1,341 children aged ≥ 6 months - ≤5 years in 24 clusters, households
41 were given transfluthrin or placebo passive emanators. Monthly blood screening and biweekly
42 human-landing mosquito catches (HLC) were performed during 10-months baseline (June 2015
43 to March 2016) and a 24-month intervention period (April 2016 to April 2018). Screening
44 detected 164 first-time malaria infections and an accumulative total of 459 infections in 667
45 subjects in placebo-control households; and 134 first-time and 253 accumulative total infections
46 among 665 subjects in active intervention households. The 24-cluster protective effect of 27.7%
47 and 31.3%, for time to first-event and overall (total new) infections, respectively, was not
48 statistically significant. Purportedly, this was likely due in part to zero to low incidence in some
49 clusters, undermining the ability to detect a protective effect from spatial repellent intervention.
50 Subgroup analysis of 19 clusters where at least one malaria infection occurred during the
51 baseline showed 33.3% and 40.9% (statistically significant at 1-sided 5% significance level; p
52 =0.0236) protective effect to first-infection and overall infections, respectively. Among 12
53 moderate- to high-risk clusters, a statistically significant decrease on infection by the spatial
54 repellent was detected (60% protective efficacy). Primary entomological analysis of impact was
55 inconclusive and proved not statistically significant. While this study suggests protective effects
56 of the intervention, additional evidence is required to demonstrate that spatial repellents provide
57 an operationally feasible and effective means of reducing malaria transmission.

58

59

60 **INTRODUCTION**

61 It has been nearly 75 years since the role of spatial repellency (deterrency or avoidance)
62 was first described as a potentially beneficial attribute in malaria control, showing chemicals
63 could effectively disrupt normal host-seeking mosquito behavior and interrupt contact with
64 humans, thus preventing disease transmission.[1-3] Spatial repellency is used here as a general term
65 to refer to a range of insect behaviors induced by airborne, volatile chemicals that ultimately
66 result in a reduction in human-vector contact. These behaviors include movement away from a
67 treated space with chemical stimulus, interference with host detection (attraction-inhibition)
68 and/or interference with feeding response (feeding-inhibition).[4-7] Spatial repellency can be
69 measured and distinguished from other chemical actions, primarily contact irritancy and toxicity,
70 in the laboratory[8, 9] and in semi-field evaluations.[10, 11] Which behavior is elicited by a volatile
71 chemical depends on the concentration or dose-exposure interaction by the mosquito in the
72 treated space. For example, toxicity occurs at higher chemical doses while deterrence (behavioral
73 avoidance) can result from lower, sub-lethal chemical concentrations.[12] Currently, the majority
74 of commercial spatial repellent products utilize either low concentrations of short-duration
75 United States Environmental Protection Agency (USEPA) registered synthetic pyrethroids
76 (pyrethrin, metofluthrin and more recently transfluthrin)[13] or botanical-based compounds.[14, 15]

77 The World Health Organization (WHO) Vector Control Advisory Group (VCAG)
78 assesses evidence on the epidemiological effectiveness of new vector control interventions and
79 by doing so supports WHO's development of policy recommendations, including the potential
80 use of spatial repellents as a public health vector control strategy.[16] Reviewed by VCAG since
81 2014, the assessment of rigorous epidemiological evidence for endorsing a policy
82 recommendation of a spatial repellent intervention class remains limited and deemed

83 insufficient.[17] A malaria prevalence study in China evaluating mosquito coils containing 0.03%
84 transfluthrin demonstrated a 77% reduction in human *Plasmodium falciparum* cases[18] and the
85 use of coils containing 0.00975% metofluthrin provided 52% protective efficacy (PE) against
86 new (incident) malaria infections in Indonesia.[19] Although primary outcomes from both studies
87 were encouraging, neither met the required VCAG evidence for full pubic health assessment
88 either due to lack of rigor in study design (small cluster number in Indonesia) and/or being
89 underpowered (both studies).[20] The importance of a WHO policy for implementation of spatial
90 repellents in malaria control programs could dramatically increase investments by private
91 industry to develop chemicals that operate through modes of actions to elicit vector behavior
92 changes other than purely toxicity. This would potentially introduce a new generation of
93 effective active ingredients and product formulations into the disease control/eradication
94 arsenal.[21, 22] In combination with existing WHO-recommended malaria control interventions,
95 spatial repellents have the potential to add significant protective benefit, especially where
96 traditional long-lasting insecticidal nets (LLINs) or indoor residual spraying (IRS) may not be
97 sufficiently protective (e.g. early-evening blood feeding vectors when LLINs are not in use
98 and/or where vectors do not or limit resting time indoors on insecticide-treated surfaces), be
99 unavailable, or are impractical and/or infeasible (emergency relief operations). Control or
100 elimination of malaria in these circumstances will require innovative approaches; as example
101 spatial repellents providing a highly beneficial protective role against transmission.[23, 24]
102 The current claim of a spatial repellent intervention class for public health value is
103 *'deployment of a spatial repellent will prevent human-vector contact to reduce pathogen*
104 *transmission'*. The role of spatial repellency in public health is dependent on assessing whether
105 or not human protection is rigorously evidenced, thus the requirement of clinical trials using a

106 prototype spatial repellent product for the intervention class. With this epidemiological primary
107 endpoint in mind, the objectives of the current RCT were to build upon previous epidemiological
108 findings and provide rigorous evidence of a spatial repellent that provides a sufficient protective
109 effect against malaria infection risk and demonstrate risk reduction by decreasing relevant
110 entomological measures (e.g., anopheline human landing (biting) density, age-grading parity
111 and/or sporozoite infectivity rates) in endemic communities. The rationale for conducting the
112 RCT at Sumba Island stems from an essential requirement by WHO VCAG that more evidence
113 of human health impact is needed to recommend a WHO global public health spatial repellent
114 policy and that such evidence should come from varied malaria endemicity settings (low,
115 moderate and high).[16] The underlying reason for integrating entomological measures (above) in
116 the RCT was to identify correlations, if any, with PE which could then be used in future trials
117 with appropriate minimum thresholds required to demonstrate non-inferiority of next-generation
118 spatial repellent products.
119

120 **METHODS**

121 The study was registered in clinicaltrials.gov (Identifier: NCT02294188) and performed
122 according to The International Conference on Harmonisation's (ICH) Guideline for Good
123 Clinical Practice (GCP; document E6) (R1) and The OECD Principles of Good Laboratory
124 Practice (GLP) based on The National Agency of Drug and Food Control, Indonesia regulations.
125 There were no changes to methods after trial commencement.[25, 26]
126

127 **Ethics statement.** Ethical review and approval for this study was granted by the Ethics
128 Committee (EC) of the Faculty of Medicine, Universitas Hasanuddin (Protocol #UH14070385),

129 the University of Notre Dame (Protocol #14-01-1448) and endorsed by the Eijkman Institute
130 Research Ethics Committee, Jakarta, Indonesia. Consent was obtained from parents or guardians
131 of child recruits following EC guidelines. For sentinel households participating in entomological
132 collections, signed consent was sought from the head-of-household. No data on individuals was
133 collected during the entomological collections. During the consenting process, the study was
134 described and the relevant consent form read in local dialect by study staff. The consent form
135 detailed the design of the study including radical cure, the purpose of collecting and storage of
136 blood samples (towards laboratory-based malaria diagnosis), descriptions of the study risks,
137 benefits, and procedures of therapeutic radical cure and follow-up. For households recruited for
138 entomology measures, the consent form detailed the design of mosquito collections and
139 descriptions of study risks, benefits and procedures of human landing catch (HLC).
140 Participants who were illiterate were asked to appose their thumbprint and, when
141 possible, a literate witness was asked to sign (i.e., a witness selected/known by the participant
142 and having no connection to the research team). All households were provided with a signed
143 copy of the consent form after agreeing to participate in the study. Adverse events were captured
144 during participant follow-up and entomological collections and reported to monitoring
145 authorities in accordance with the approved protocol. All participants were free to drop out of the
146 study at any time, regardless of reason or having to provide one, and without prejudice.
147
148 **Study setting.** The study was conducted in Southwest and West Sumba districts, East Nusa
149 Tenggara Province, Indonesia (**Figure 1**). The circa 400,000 residents of the two districts occupy
150 175 village 'groups' (*desas*) and several small-sized towns.[27] Thirteen village groups, with
151 resident populations ranging between 1,067 and 3,904 (avg. 2,132), served as study locations for

152 the final selection of the 24 study clusters consisting of multiple desas. Organized bed net
153 campaigns were recently introduced with the last mass distribution occurring in February-March
154 2018 across the study area. A mass distribution of long-lasting insecticidal nets (LLINs) occurred
155 in October-December 2014 in both districts (Olyset Net® (Olyset Net®, permethrin 2.0% w/w)
156 with a reported > 95% coverage of households provided 1-4 nets each. A second round of LLIN
157 mass distribution occurred February-March 2018 (PermaNet® 3.0, deltamethrin 180mg/m2 +
158 PBO synergist). The last round of focal IRS occurred in 2003 using a pyrethroid-based product.
159 The malaria prevalence based on microscopically diagnosed parasitemia drawn from a random
160 sample of 50% of residents present in 13 villages conducted in 2015, 10 months before the
161 intervention trial, averaged 15.5% (2.5% to 37.3%) (**Table 1**).

162 Although very little detail is known about the malaria vector distribution and bionomics
163 in this study area,[28] an earlier (August 2007) entomologic survey documented 13 species of
164 anophelines occurring in West Sumba district: *Anopheles aconitus* (Dönitz), *Anopheles annularis*
165 Van der Wulp, *Anopheles barbirostris* s.l. (Satoto), *Anopheles flavirostris* (Ludlow), *Anopheles*
166 *hyrcanus* group (Reid), *Anopheles indefinitus* (Ludlow), *Anopheles kochi* (Dönitz), *Anopheles*
167 *leucosphyrus* group (Reid), *Anopheles maculatus* Theobald, *Anopheles subpictus* s.l. Grassi,
168 *Anopheles sundaicus* s.l. (Dusfour et al.), *Anopheles tessellatus* Theobald, and *Anopheles vagus*
169 Dönitz.[29] These species vary spatially in relative abundance associated with presence of their
170 preferred aquatic larval habitats ranging from coastal brackish and freshwater marshes and
171 ponds, seasonally productive rice paddies, to forested hillsides with perennial running streams
172 and small rivers. At the time of the survey, human-landing collections revealed *An. subpictus* and
173 *An. vagus* as the predominant species in the upland interior locations, and *An. sundaicus* as the
174 most common species attracted to human along the coastal plain. The majority of residents in

study villages work as small-holder agriculturalist pursuits, typically lacking public supplied electricity or articulated water supply systems. Homes are predominately traditional designed, large, thatched-roof structures raised ~1m above ground, averaging ~70 m^3 in size (6 m length x 6 m width x 2 m in height) and constructed with gaping bamboo walls and flooring that offer little protection from mosquito entry (**Figure 2**).

Trial design. The study was a randomized cluster, double-blind, placebo-controlled, clinical trial with a total of 24 clusters divided into 12 clusters per intervention arm. The primary outcome of the study was to demonstrate and quantify the protective efficacy (PE) of a spatial repellent product in reducing the incidence of malaria infection in a human cohort. The null hypothesis was that there is no difference in malaria incidence between intervention and control arms. Clusters were selected based on housing type, focusing on traditional houses (with or without thatch roofing) (**Figure 2**), mitigation of potential chemical dispersion 'spillover' effect (i.e., distance between nearest homes in different clusters ~500 m apart), and logistical considerations (i.e., distance from field-based satellite laboratories). About fifty-four households were recruited within each cluster based on human sample size requirements. Households from 13 villages were stratified into 24 clusters before randomization: Gaura (pop. 2,831; houses 432), Kahale (pop. 3,904, houses 253), Karang Indah (pop. 1,169, houses 139), Manutoghi (pop. 1,067; houses 165), Matakapore (pop. 2,805; houses 209), Panenggo Ede (pop. 1,271; houses 90), Rada Malando (pop. 1,842; houses 133), Tana Mete (pop. 2,124; houses 213), Waikarara (pop. 2,709; houses 446), Wailangira (pop. 1,878; houses 226), Waimakaha (pop. 2,334; houses 211), Waimaringi (pop. 2,598; houses 116), and Weetana (pop. 2,670; houses 275) (**Figure 3**).

198 **Sample size.** Previous malaria incidence rates collected in a portion of the study area in coastal
199 Kodi Subdistrict were used to estimate the likely malaria attack rate in the current study villages
200 at 0.3 infections/person-year.[19] Sample size determination was based on the hazard rate
201 comparison in the proportional hazards regression model.[30] The required number of first-time
202 infections was estimated at 417 to permit detection of a 30% protective effect by the spatial
203 repellent intervention compared to placebo with 80% power at the type-I error rate, assuming a
204 between-cluster coefficient of variation (CV) of 30% and a baseline hazard rate of 0.3 per
205 person-year. With 12 clusters per treatment arm (active or placebo), with 2-month accrual and 22
206 months follow-up, and an estimated 20% loss-to-follow-up (LTFU) during intervention, a total
207 of 54 subjects per cluster was required (n=1,296). As entomology measures were used in
208 relationship analyses of PE rather than hypothesis testing, sample size was based on field
209 logistical capacity and not for statistical power.
210
211 **Participants**. The average number of children ≤5 years of age in each cluster was 68 (57-79).
212 From individual households in study clusters, one child, aged ≥6 months - ≤5 years at time of
213 recruitment, were provided the opportunity to enroll as subjects in the study. Following informed
214 consent, medical screening consisted of physical examination by a study physician and a
215 qualitative NADPH spot test for G6PD deficiency (Trinity Biotech qualitative G6PD assayTM,
216 ref 345-UV, Trinity Biotech, St. Louis, MO).[31] Additional to being G6PD normal status,
217 eligibility requirements included a bodyweight ≥ 40 kg, hemoglobin > 5mg/dL (Hb201+,
218 HemoCue AB, Angelholm, Sweden),[32] no severe acute illness/infection on the day of inclusion,
219 temperature ≤ 38°C, participant acknowledging sleeping in the village > 90% of nights during

220 any given month, not participating in another clinical trial, and with no intensions for extended
221 travel during the study period.
222
223 **Intervention.** Immediately after completion of radical cure, intervention was simultaneously
224 initiated in all subject households and non-subject households that consented to receive
225 intervention. The spatial repellent intervention is a transfluthrin-based passive emanator
226 produced by S.C. Johnson & Son, Inc (SCJ) designed to release a volatile chemical into the air
227 and prevent human–vector contact by disrupting normal behavior of mosquitoes within the
228 treated space. The indoor placement of the intervention product was designed with the objective
229 to measure PE under indoor use conditions. Transfluthrin is a registered compound commonly
230 found in commercially available mosquito coils globally based on WHO specifications.[33] The
231 U.S. Environmental Protection Agency (EPA) has recently approved transfluthrin products for
232 indoor use with the USA.[34] Emanators (active and placebo) of identical packaging and color
233 were distributed by study personnel every 2 weeks at the individual household application rate of
234 2 units / 9m^2 according to SCJ specifications. There was a median of 1 room (range 1,9) and 10
235 emanators (range 4,56) per household. Intervention devices were positioned indoors by hanging
236 individual emanators on two metal hooks specially attached to walls for this study. Each position
237 remained static throughout the study. The hooks facilitated stabilization of the interventions so
238 the chemical-treated surface was consistently exposed facing the interior space. Research staff
239 placed, removed and replaced emanators in households at set intervals and recorded attrition,
240 based on number of products removed from each structure during each replacement period, to
241 ascertain application rate for use in estimating cluster coverage. During the trial period, quality
242 control analysis was performed by Ross Laboratories, India on unused (in storage) emanators to

243 verify amount of transfluthrin in actives and the absence of transfluthrin in placebos. At the end
244 of follow-up period (April 2018), used, unused and expired emanators were disposed of by PT.
245 Wahana Pamunah Limba Industri in Jakarta according to Indonesian regulations on disposal
246 requirements.
247
248 **Randomization, allocation and blinding.** Clusters were allocated to receive either active or
249 placebo treatment using a random number generator (https://www.random.org). The cluster
250 allocation code was made available from the intervention manufacturer to the Data Safety
251 Monitoring Board (DSMB) for use in safety assessments. The site database manager assigned a
252 unique identification number to each household (HIN) and the site intervention administrator
253 coordinated distribution of blinded active or placebo to enrolled households within each cluster
254 corresponding to the pre-labeled package code. Unblinded assignments were shared with a site
255 administrator in a sealed envelope placed in a secure location within the managing center of the
256 research project (Jakarta) for purposes of emergency unblinding related to adverse and serious
257 adverse events. Thus, the investigators, research team, study subjects, and residents were blinded
258 as to which cluster received active versus placebo devices until after completion of the study.
259
260 **Procedures**.
261 *Radical cure and follow-up.* **Figure 4** summarizes screening, enrollment, and follow-up of the
262 incidence density cohorts. A total of 1,353 subjects were presumptively radically treated using a
263 fixed combination formulation of dihydroartemisinin (DHA)-piperaquine (P) (containing 40 mg
264 dihydroartemisinin and 320 mg piperaquine (Zhejiang Holley Nanhu, Beijing Holley Cotec)
265 administered as a weight per dose regimen of 2.25 and 18 mg/kg per dose of dihydroartemisinin

266 and piperaquine, respectively, once daily for 3 days. Primaquine (PT, Pharos Tbk, Semarang,
267 Indonesia) 0.25 mg/kg body weight was prescribed for the 14 days immediately before
268 implementing intervention. The DHA-P combination is currently the first-line antimalarial drug
269 for uncomplicated malaria treatment in Indonesia. All subjects were examined for *Plasmodium*
270 spp. infection by expert microscopy, and later confirmed using polymerase chain reaction (PCR)
271 from matched filter paper blood spot samples.[35] New malaria infections among the participants
272 were monitored every 4 weeks using microscopic examination of Giemsa-stained blood films
273 according to WHO guidelines based on a minimum of 200 high magnification (1000x oil-
274 immersion) thick blood film fields.[36] Two certified expert microscopists independently (blinded)
275 examined slides on-site at project-dedicated field laboratories. PCR detection of parasite DNA
276 was conducted at the Eijkman Institute for Molecular Biology (EIMB) central laboratory in
277 Jakarta for all four *Plasmodium* species.[35] A blood sample was defined as malaria 'positive' for
278 inclusion in incidence analyses if meeting criteria of having two diagnostic outcomes indicating
279 presence of parasite (e.g., 2x microscopy; 1x microscopy + 1x PCR; or 2x PCR). All positive
280 and 10% randomly selected negative samples diagnosed at EIMB were re-tested at the
281 University of Notre Dame. Discordant microscopy and PCR results required reexamination of
282 both initial findings. Participants found malaria infected at point-of-care were immediately
283 treated with DHA-P and were removed from contributing further to person-time at risk of first-
284 time infection; however, they remained in the study to monitor cumulative incidence for analyses
285 of overall (total new) infections and estimate number of cases averted.
286
287 <u>*Entomologic surveys.*</u> In a subset of 12 clusters, adult mosquito diversity and densities were
288 measured using human-landing catches (HLC) every two weeks from start of baseline through

289 end of follow-up period in a subset of 12 clusters. Clusters for entomological sampling were
290 selected based on exhibiting highest HLC densities during baseline sampling, along with
291 existence of mosquito larval habitats. The 12 clusters were hierarchically stratified on criteria of
292 baseline human landing catch then blindly allocated to treatment arm to ensure a balanced
293 recruitment (6 clusters in each treatment group). Four neighboring sentinel houses within each of
294 the 12 clusters were randomly selected for mosquito collections (n=48). Collections were
295 conducted at sentinel houses for 1 night every 2 weeks from paired active/placebo clusters (e.g.,
296 3 pairs on Monday night and 3 pairs on Wednesday night) during intervention. Teams of two
297 collectors were assigned per house, one positioned indoors near the center of the house and one
298 located outside on the house verandah, approximately 1 m from the exterior wall. Collectors
299 removed all mosquitoes landing on their exposed lower legs using a mouth aspirator. Collections
300 were conducted from 1800 to 0600 h for 50 min every hour. Paired collectors rotated between
301 indoor and outdoor positions each hour. Samples were placed into individual holding containers
302 labeled by collection hour, unique house code (linked to blinded treatment code), and collection
303 location (indoor or outside). Captured mosquitoes were immediately killed by ether-soaked
304 cotton pads in the field and initially identified to species (or species complex) using
305 morphological characters.[37] All specimens were transported to an on-site base laboratory upon
306 completion of the 12 h collection and a random sample of representative anopheline species (up
307 to 20% per cluster per indoor/outdoor location and hour of collection) were dissected for parity
308 and scored as either gravid/parous or nulliparous.[38] Partial (head-thorax for those dissected for
309 parity) or whole anopheline specimens were placed singly into individual Eppendorf® 1.5ml
310 vials and stored over silica gel desiccant until further processing at EIMB, Jakarta, for detection
311 of malaria sporozoites and molecular-based species identification, where applicable.[39, 40]

312 Mosquito samples were evaluated for *Plasmodium* species infection using polymerase chain
313 reaction (PCR) methodologies to derive corresponding malaria sporozoite infection rates by
314 parasite and vector species.[41] Together with time-adjusted HLC densities (anophelines/person-
315 night), matched sporozoite rates were used to derive the entomological inoculation rates (EIRs)
316 for each treatment arm.[42] Anopheline species identification was verified at the University of
317 Notre Dame following previous protocols (not reported herein).[39, 40]
318
319 *Insecticide susceptibility assays.* Permethrin was evaluated using the WHO standard tube and
320 CDC bottle assay during baseline, intervention and post-intervention periods at the WHO
321 recommended discriminating concentration for anophelines 0.75% and CDC recommended dose
322 21.5µg/ml active ingredient.[40, 41] Both WHO tube assays and CDC bottle assays were
323 performed on F0 mixed anopheline species collected as immatures in 13 of the 24 study clusters
324 from across 23 habitat locations during baseline, intervention and 6-mo post-intervention period
325 (ending Oct 2018). Assays were conducted using non-bloodfed, 3-5 day old females according to
326 established guidelines.[43, 44] After each test period, all chemical and control specimens were
327 stored individually over silica gel for analysis at EIMB to confirm species identification and for
328 detection of target-site mechanisms (e.g., *kdr* gene mutations) of resistance (not reported herein).
329
330 *Monitoring of adverse events (AE) and serious adverse events (SAE).* AEs, possibly related to
331 transfluthrin exposure, in subjects and other household members, were captured by the study
332 team during both active and passive blood sampling using a standardized survey form.
333 Investigation of study-related AEs was performed by the on-site study clinician. SAEs were also
334 recorded according to protocol, regardless of possible relationship to intervention. Government

335 clinic health records were compiled on a quarterly basis starting in December 2017 for DSMB
336 safety assessment of the study population.
337
338 *Data management and verification.* Data collection was designed around a tablet-based survey
339 platform linked to a custom-built database and web portal. CommCare (Dimagi Inc, MA, USA)
340 was selected as the frontend form application, providing critical capabilities, including: a parent-
341 child case structure, the ability to store forms when offline, update form versions after
342 deployment, build forms with complex logic in a web browser, and export form data to other
343 tools. Data was cleaned according to rules specified in the study protocol to ensure data
344 integrity. Study data related to participating subjects and households, intervention
345 (placement/replacement activity), mosquitoes collected, and lab analyses was cross-checked,
346 identifying missing, incomplete, or suspect data submissions. These data were relayed to the site
347 data manager to be resubmitted or corrected. Once data correction was complete, data was
348 verified and requested for analyses.
349
350 **Outcomes and statistical methods (S1. Statistical Analyses Plan).** The *primary endpoint* for
351 estimating the protective efficacy (PE) of the spatial repellent intervention was malaria incidence
352 (time to first infection) among study participants in each of the 24 clusters. All participants, living
353 in separate households, received a directly observed, presumptive radical cure over a 14-day period
354 to clear them of any standing (patent, sub-patent, or latent) malaria infections. Subsequent
355 biweekly blood film examinations were conducted from subjects reporting fever within the
356 previous 48 hours (active case detection) with routine screening for malaria infection in all subjects
357 (passive case detection) occurring every 4 weeks for the duration of the study. Study participants

358 were excluded from analyses when lacking a blood sample during the intervention period or when
359 a household might have contributed more than two subjects. In the latter case, this occurred (rarely)
360 when there was loss-to-follow-up (LTFU) on the first recruited subject and a second subject was
361 recruited as a replacement; only the subject with a longer follow-up period was used based on per-
362 protocol allowing only one subject per household.

363 The *primary hypothesis* on PE against first-time malaria infection was tested by comparing
364 the hazard rates of the first-time malaria infection between active and placebo (blank) intervention.
365 The complementary log-log (cloglog) regression model $\log\left(-\log\left(1-\theta_{ijt}\right)\right) = \beta_{0t} + \boldsymbol{x}_{ijt}^{t}\beta +$
366 z_i was.[45-48] θ_{ijt} is the discrete time hazard rate of subject j in cluster I at time t, $\boldsymbol{x}_{ijt}$ contains visit
367 (as a categorical predictor), the individual-level (age, gender), household-level (number of doors,
368 open eaves Y or N, wall type), and cluster-level (baseline incidence rate, cluster population size,
369 intervention group) covariates, and $z_i \sim N(0, \sigma^2)$ is the cluster-level random effect. PE was
370 estimated by $((1-\exp(\hat{\beta}))100\%$ with a 90% confidence interval (CI) based on the Wald test,
371 where $\hat{\beta}$ is the estimated regression coefficient associated with the intervention group, and $\exp(\hat{\beta})$
372 is the estimated hazard ratio (HR) between active and placebo. The null hypothesis that PE is 0
373 was tested by the Wald's test $z = \hat{\beta}/s$,, where s is the estimated standard error of $\hat{\beta}$. It was
374 concluded that active intervention reduces the first-time malaria hazard rate compared to placebo
375 if $z < z_{0.05} = -1.645$; otherwise, the study would not have sufficient evidence to suggest that
376 active intervention reduces the first-time malaria hazard rate compared to placebo at a one-sided
377 significance level of 5%. The Kaplan-Meier (KM) curves on time to first infection per cluster was
378 provided for the active and placebo arms, respectively.

379 The statistical analysis of *the secondary endpoint* of the overall (total new) malaria
380 infections detected in study subjects was similar to that used for analyzing the primary endpoint

381 of the first-time malaria infection except that the above cloglog model has additional term $z_{j(i)}$,
382 which is the random effect at the individual level to account for the dependence among multiple
383 malaria infections per individual. The same set of analyses as described above were performed in
384 a subgroup analysis in clusters with non-zero baseline incidence rates and those clusters with
385 entomology data.

386 The effects of active intervention on the *secondary entomological endpoints* were
387 estimated using a negative binomial regression model, if applicable. Specifically, the *anopheline*
388 *landing rate* (surrogate 'bite' based on HLC and indicator of human-vector contact) is defined as
389 the number of mosquitos captured during a 12-hr evening interval (1800-0600)**.** The covariates in
390 the model include the fixed effects of intervention group, the interaction between treatment and
391 location of collection (inside or outside), visit (as categorical), baseline incidence rate, baseline
392 vector count, cluster population, and random effects for household nested within cluster and for
393 cluster. The percentage change in human landing rate by intervention was estimated from the
394 model. The frequencies and percentages of captured anophelines were also summarized by species.
395 The set of covariates in the model for analyzing the *parity rate* are similar to the landing rate
396 model, with an additional offset term for the daily landing rate. Due to data sparsity for the
397 *sporozoite positivity rate* (> 99% of tested mosquitos were uninfected), no model-based analysis
398 was performed and only summary statistics are provided. The *entomological inoculation rate*
399 *(EIR)* is defined as the number of malaria infective mosquito bites a person receives per a unit time
400 (typically annually) and calculated as $\text{EIR} = \text{sporozoite positivity rate} \times \text{human biting rate}$. The
401 observed data sparsity experienced with low sporozoite positivity also impacts the EIR results, and
402 thus only summary statistics are provided for EIR.

403 LLIN usage, measured from responses to the question: *"Did you use a bed net last night?"*
404 was included as a covariate in the model for PE as a supplementary output.
405

406 **RESULTS**

407 **Protective effect against malaria infection (pre-planned).**

408 Trial outcomes show baseline covariates regarding subject, house construction,
409 population and baseline malaria incidence between the active and placebo arms were balanced at
410 the individual-, household-, and cluster-level in the all 24 cluster analyses (**Table 2**). The
411 intervention coverage rate, defined as the proportion of actually placed emanators over the total
412 number required per household, ranged from 82.2% to 98.6% by cluster over the entire
413 intervention period, with a mean application rate of 93.2% and 92.3% for the active and placebo
414 arms, respectively. The percent of LLIN usage per household during the trial, defined as
415 responding 'Yes' to the question: *"Did you use a bed net last night?"*, ranged from 14.6% to
416 99.8% in clusters that received active intervention and 17.4% to 99.8% in clusters that received
417 placebo (**S2. LLIN Usage**).

418 There were 134 first-time infections among 665 subjects in active intervention
419 households and 164 first-time infections in 667 subjects in placebo-control households, with a
420 27.7% decrease in the first-time malaria hazard risk using active compared with placebo (90%
421 CI: -21.3%, 56.9%) (**Table 3**). The 27.7% PE was not statistically significant at the 5% one-
422 sided significance level ($p = 0.151$). The estimated PE of active intervention against overall
423 (total) malaria infections (first and subsequent) was 31.3% (90% CI: -10.8, 57.4%) with a one-
424 sided p-value = 0.098 (**Table 3**). Investigation of potential shift in parasite species infection

425 frequency (*P. falciparum* vs. *P. vivax*) between active and placebo arms will be reported in
426 subsequent publications.

427 A total of 164 first-time malaria infections occurred during approximately 1032 person-
428 years at risk in study participants whose households were given placebo, with a calculated
429 incidence density of 0.159 infections/person-year (**Table 3**, **Figure 5**).[49] In contrast, 134 total
430 malaria attacks occurred in transfluthrin-active households with approximately 1079 person-
431 years at risk resulting in a calculated 0.124 infections/person-year. A cumulative 439 malaria
432 infections (first-time and subsequent) during approximately 1216 person-years at risk in
433 participants with households provided placebo, produced an incidence density of 0.361
434 infections/person-year. Contrastingly, 253 total (accumulative) malaria attacks occurred among
435 participants living in active intervention households with approximately 1216 person-years at
436 risk equaling 0.209 infections/person-year (**Table 3**).

437

438 **Subgroup analyses of protective effect against malaria infection among non-zero incidence**
439 **and entomology clusters (not pre-planned).**

440 Among the 24 clusters, there were five clusters with zero baseline incidence having had
441 zero to very low incidence rates during intervention. The first subgroup analysis used the 19
442 clusters with non-zero incidence rate as the remaining five clusters may have been excluded from
443 the intervention if baseline analysis had been performed before randomization. Excluding these
444 five clusters, the estimated PE for overall (total new) infections in the remaining subgroup of 19
445 clusters with non-zero baseline incidence rates was 40.9% (90% CI: 8.61, 61.8%) resulting in a
446 one-sided *p*-value of 0.0236 (**Table 3**). The second subgroup analyses included incidence from
447 the 12 clusters having routine entomology collection data (i.e., mean anopheline landing

448 rate/person), and where the average baseline incidence was approximately 4 folds greater than
449 the other study clusters. The PE using active intervention against time to first-event and overall
450 (total new) malaria infections in this subgroup was 55.3% (90% CI: 33.6, 69.9; *p*-value <0.0004)
451 and 66% (90% CI: 49.2%, 76.7%; *p*-value <0.0001), respectively (**Table 3**). The data indicate
452 the baseline covariates (subject, house construction, population and baseline malaria incidence)
453 between the active and placebo arms were balanced at the individual-, household-, and cluster-
454 level in the 19 non-zero incidence and 12 entomology cluster subgroup analyses (not shown).
455
456 **Effects on entomological endpoints.**
457 Results presented are summary outcomes on aggregated anopheline species captured
458 using HLC. Detailed data analyses on effects of this intervention on entomology measures is
459 forthcoming in subsequent publications, to include temporal change in species-specific
460 anopheline vector composition over the trial period, relative abundance between treatment arms
461 by species, and the HLC of non-anophelines (culicine mosquitoes).
462
463 *Anopheline landing rates.* A total of 52 weeks of HLC were performed within a subset of 12
464 clusters during the intervention period. Results based on morphological species identification
465 detected 19 putative malaria vector species showing spatial and temporal variation across
466 monitored clusters. The most common anopheline species (s.s. or s.l.) attracted to humans
467 included: *Anopheles aconitus*, *An. annularis*, *An. barbirostris*, *An. flavirostris*, *An. kochi*, *An.*
468 *maculatus*, *An. subpictus, An. sundaicus*, *An. tessellatus* and *An. vagus* (**S3. Anopheline**
469 **Frequency Summary**). The cumulative indoor (n=8,780) and outdoor (n=9,207) anopheline
470 landing rates across both baseline and intervention sampling periods are shown in **Figure 6**.

471 There was a numerical reduction in indoor and outdoor landing density from collections
472 performed in households provided active intervention (n= 3,883 and 4,373, respectively)
473 compared with placebo households (n= 4,897 and 4,834, respectively). The reduction in
474 anopheline attack rate on collectors positioned indoors and outdoors, at sentinel households with
475 active intervention compared with placebo houses was not statistically significant: 16.4% (95%
476 CI = -75.2%, 182.7%; p = 0.774) and 11.3% (95% CI = -73.7%, 199.4%; p =0.847), respectively
477 (**Table 4**).
478
479 *Sporozoite positivity rate and Entomological Inoculation Rate (EIR).* A total of 11,928 and
480 17,986 anopheline samples from baseline and intervention follow-up periods, respectively, were
481 processed for malaria sporozoites. The frequency of sporozoite positive anophelines is provided
482 in **Table 5.** Only *P. falciparum* and *P. vivax* infections were detected in captured mosquitoes.
483 During baseline and intervention period, the sporozoite rate was less than 0.5% for both
484 treatment and placebo arms. Data sparsity regarding comparison of sporozoite rates precluded
485 inferential statistical analyses. The EIR was <1 bite per year in both treatment arms during
486 baseline and intervention periods.
487
488 *Parity rate (age-grading).* A total of 15,828 anopheline samples were dissected for parity status
489 during the trial period (**Table 6**). The proportion of females categorized as "older," combining
490 parous and gravid states (mosquitoes with advanced ovarian follicle development as evidence of
491 a recent blood meal), and those "younger" as nulliparous (non-bloodfed) and more recently
492 emerged, were compared between active and placebo treatments for the 12 clusters with
493 entomological monitoring was conducted. Overall, transfluthrin-active emanators proportionally

494 increased nulliparity in the sampled anopheline populations compared to placebo for both indoor
495 and outdoor locations (**Table 6**).
496
497 <u>*Insecticide susceptibility.*</u> A total of 5,091 adult female anophelines (chemical and control
498 bioassays) were evaluated for susceptibility: 700 samples during baseline, 1,805 during
499 intervention and 2,586 post-intervention. *Anopheles vagus* was the most widely distributed and
500 tested anopheline (56%), followed by *An. sundaicus* (12.6%) and *An. subpictus*, *An. barbirostris*,
501 *An. kochi*, *An. aconitus*, *An. maculatus*, and *An. tessellatus* (proportionally, all < 10%). In the
502 CDC bottle bioassay, baseline, intervention and post-intervention tests using permethrin
503 (21.5ng/ml) showed 100% knockdown between 15-30 min exposure and within the
504 recommended diagnostic time. In the WHO tube bioassay with rare exception, there was 100%
505 24hr mortality to permethrin 0.75% following 60 min exposure. Based on the assumption of
506 predominately pyrethroid-susceptible wild populations of *Anopheles* species present in trial sites,
507 there was no conclusive evidence of the development of phenotypic resistance to pyrethroid class
508 chemicals between pre-and post-intervention periods. Interestingly, in several clusters during the
509 post-intervention phase, there were indications of reduced permethrin susceptibility (WHO
510 bioassay) in a few *An. barbirostris* populations to permethrin. Follow-up investigations provided
511 inconsistent results, thus confirmation that these focal populations showed low levels of
512 resistance could not be verified. The determination of presence or absence of target-site
513 mechanisms for resistance will be reported separately.
514
515
516

517 **Adverse Events (AE) and Severe Adverse Events (SAE).**

518 Using government clinic health records, a total of 523 AEs were reported from non-participants
519 while 144 AEs were reported from the intervention study cohort captured by the study team. Of
520 subject AEs, 52 were reported from participants in the active intervention arm and 92 from
521 placebo clusters. General respiratory complaints were most common for all reported AEs,
522 followed by general fever. There were 6 total SAEs reported in the overall study cohort during
523 follow-up: one death due to suspected brain infection; one death from respiratory infection; one
524 death from malaria with concomitant bacterial or viral infection; one death by drowning, and two
525 deaths of unknown cause.

526

527 **Intervention Quality Control.**

528 A total of 180 unused emanator samples were analyzed in 2017. Samples were taken from 12
529 different active and placebo clusters with manufacturing dates ranging from April to November
530 2016 (15mo to 8mo-old samples). All sampled placebo interventions (n = 48) were found to be
531 absent for transfluthrin. The average transfluthrin quantity from all sampled active emanators (n
532 = 132) was 54.3 mg, which was within the specification range (55.0 mg ± 2.75 mg).

533

534 **DISCUSSION**

535 Malaria remains a significant global public health burden despite recent progress in reducing
536 transmission rates.[50] The primary objective of this large-scale RCT conducted on Sumba Island,
537 Indonesia was to demonstrate and quantify the protective efficacy (PE) of a passive emanating
538 spatial repellent intervention (transfluthrin-treated), for reducing malaria incidence
539 (transmission) in humans. Such epidemiological evidence of health impact is a fundamental

540 requirement in the critical path of development of new vector control intervention classes being
541 assessed by the WHO VCAG.[16] Sumba Island, Indonesia was selected as the study site based on
542 WHO VCAG requirements of assessing evidence from varied endemic settings where spatial
543 repellents are intended to be implemented if/when a policy recommendation is endorsed. In
544 addition, Sumba does not currently conduct routine IRS and LLINs were only recently
545 distributed.

546 The primary per-protocol analyses provide an estimate of 27% PE against malaria
547 infection, which is near the efficacy of 30% selected in the power calculations. This effect,
548 however, was not statistically significant with confidence intervals that include zero. There were
549 298 first-time infections, in contrast to an expected number of at least 417 assumed in the sample
550 size calculations, thus resulting on the trial being underpowered. The demonstration of spatial
551 repellency PE (66%) against total new infections in the subset of 12 clusters used for
552 entomological measures, which had approximately 4 folds greater malaria infection incidence
553 during intervention, indicates health impact where risk of malaria infection was greatest (i.e.,
554 locations with highest vector landing densities). Outcomes reported here are promising for
555 malaria control, despite the study being unable to demonstrate clear, statistically protective
556 efficacy on primary analysis, with data anticipated to be included in meta-analyses with other
557 clinical trials evaluating spatial repellents.

558 This study highlights three primary challenges for consideration in future spatial repellent
559 trials as well for new vector control intervention classes more broadly: 1) firstly, having
560 'adaptive' study designs, especially for evaluation of interventions in low to moderate malaria
561 transmission settings and/or settings with inherently large cluster-to-cluster variance on
562 transmission intensity; 2) defining and identification of the 'key' entomological correlates of

563 protection; and 3) ensuring reliability and feasibility in AE/SAE reporting for accurate safety
564 assessment. Regarding adaptive study designs, our assumptions for power and sample size
565 calculations were based on a previous proof-of-concept study that took place in an entirely
566 coastal location but was spatially very near (bordering) the current study area.[19] The study
567 villages, both coastal and further inland, were selected with the assumption that all clusters
568 delineated from these villages would experience similar levels of malaria transmission during the
569 intervention period; however, this was not the case during the trial. As in all epidemiological
570 trials, underlying assumptions of incidence used for power and sample size calculations can vary
571 from actual incidence during intervention follow-up. Baseline data analyses indicated zero-
572 incidence for five of the 24 selected study clusters with a 5-folds higher between-cluster
573 variability than assumed in the original sample size calculation. The five clusters with zero
574 baseline incidence (two allocated to receive active and three allocated to receive placebo) also
575 had either zero or low incidence rates during intervention and ranked in the top 8 among the 24
576 clusters in terms of lowest in intervention incidence (data not shown).

577 In retrospect, a pre-planned interim and final analysis of the baseline data would have
578 allowed for consideration in adjustment of the study design by filtering out the zero-incidence
579 clusters, or increasing the study duration (time of follow-up), the number of subjects recruited
580 per cluster, or the number of clusters to better satisfy requirements of statistical power and
581 capture the necessary number of outcome events (infections). However, baseline incidence was
582 measured only for verifying hierarchical stratification and use as a covariate in statistical
583 analyses of PE. This therefore, resulted in: 1) the original sample size not accommodating for
584 interim and final analyses of baseline data; 2) timelines of grant period not being projected and
585 assured to include lag-time for baseline data analyses and outcome assessment; and perhaps most

importantly 3) baseline incidence analyses not being explored early to determine variations in sample size /cluster number adjustments required to achieve sufficient study power and subsequent study site viability.

Given the updated baseline incidence rate of 0.131 per person-year and 97.1% CV, to maintain 80% power with the originally assumed 30% PE, 100 clusters per arm with 144 households (HHs; i.e. subjects) would have been required to be recruited to collect 5,550 first-time malaria events – an unmanageable scale that could not have been supported due to geographical, logistical and funding constraints. Moreover, increasing the follow-up time to collect more first-time malaria events would have neither counterbalanced the large variability nor the longer duration required to collect the additional events due to the seasonally-influenced low to moderate malaria transmission among clusters. For this reason, when planning future trials in low or moderate endemic settings, investigators should consider including a greater number of clusters per arm and/or building into the statistical analyses plan an interim and final analyses of *baseline* incidence with pre-determined study design adaptations, to include down-selection of clusters with predetermined incidence thresholds. This may become most relevant when considering proof of efficacy of an intervention in low transmission settings as a component for malaria elimination goals. Early exercises of the impact of a lower than assumed incidence (or greater CV) during study planning should be explored amongst investigators, industry and funding partners to ensure that the study area context, intervention manufacturing, program period and/or funding can sufficiently meet the demands of power requirements if adjustments are to be made once the study begins. Stakeholders should also discuss supporting and adopting adaptive designs thereby allow decision-making after planned interim analysis of *intervention* data, to either stop the trial for futility or to continue the trial with adjusted design

609 parameters, such as sample size.[51, 52] Perhaps just as important in the context of vector control,
610 although RCTs are rated as high-quality evidence,[53] considerations to RCT alternatives are
611 prudent in the trial planning phase as these may offer assurances of adequate data rigor while
612 balancing cost and time constraints of traditional RCTs.[54, 55] Alternative study designs include
613 large observational studies for detecting population-level effects using analytical cross-sectional
614 studies, or operational program-based evidence; the latter perhaps especially for interventions
615 containing an existing registered chemical active ingredient (i.e., meets human safety thresholds)
616 and where the intervention is implemented in pilot trials and impact monitored through case
617 reports, as compared to a contemporaneous control group.[55]

618 Albeit the study was not powered for entomology, the inclusion of entomological
619 endpoints in the Sumba RCT was, in part, to help understand and validate the intervention's
620 mode of action for the VCAG claim of a health impact through a reduction in human-vector
621 contact. Spatial repellent chemicals may cause initial knockdown and mortality by exposure to
622 toxic doses at close range to the active ingredient, or a delayed kill through behavioral avoidance
623 response (i.e., blood-feeding inhibition), through exposure to sub-lethal doses at distances further
624 away from the stimulus source. Therefore, entomological measurements for detecting reductions
625 in human-landing density in clusters with active intervention, and a possible change in
626 anopheline age structure (parity rate) indicating older populations not surviving as long as in
627 placebo areas, was built into this study. Additionally, a reduction in sporozoite infection rates,
628 because of lower blood feeding success, and/or an inability to survive the required time interval
629 (parasite incubation period) to become infective (transmissible) from a vector to a host, represent
630 other endpoint measures of repellency impact. A causal relationship with one, several or all, of
631 these endpoints would allow future trials evaluating non-inferiority of a 'second-in-class' spatial

632 repellent to integrate entomological measures only to predict PE and provide assurances of
633 meeting minimum thresholds of acceptance for public health use.

634 Sporozoite positivity rates and EIR estimates from the current trial were low, with a total
635 of 42 of 11,650 (0.36%) anophelines tested during baseline (10mo) and 19 of 17,971 (0.11%)
636 found infected during intervention (24mo). These findings are not unusual or unexpected in low
637 to moderate malaria transmission settings.[28] As example, the previous Sumba study (using
638 metofluthrin coils) reported just 15 out of 1,825 (0.82%) HLC anopheline samples sporozoite
639 infected.[19] The challenges for assessing sporozoite infectivity and using EIR as a measure of
640 intervention effect in such settings should be factored into study pre-planning to carefully
641 balance cost of sample processing with potential useful information gained.

642 These study findings report a 16.4% numerical reduction in indoor-landing mosquitoes
643 exposed to active treatment compared to placebo-control. Just as important was an observed
644 numerical reduction (11%) on outdoor-landing collections on the exposed verandah of sentinel
645 houses, as Sumba residents often sleep on the verandah without the protection of a bed net. It is
646 noted, however, that both indoor and outdoor HLC outcomes showed wide CIs that overlap zero,
647 making results inconclusive. A previous proof-of-concept study on Sumba that evaluated a
648 metofluthrin-active coil resulted in a significant 32% reduction in *An. sundaicus* indoor landing
649 rates as compared to a blank-coil control;[19] The minimal reduction in the human landing rate in
650 the current RCT may be the result of species-specific effects by active ingredient (i.e.,
651 metofluthrin vs. transfluthrin) but differences in HLC outcomes of the two studies on Sumba
652 should not be interpreted as the transfluthrin intervention being less efficacious than a coil. The
653 greater complexity of anopheline diversity may likely have contributed to the inconclusive HLC
654 outcomes based on aggregated anopheline data. It is expected similar results may occur in future

trials that are conducted in settings with diverse vector populations and/or as cluster size increases thereby increasing the probability of greater habitat diversity.

Specifically, the previous Sumba study was smaller in scale and *An. sundaicus* was the overwhelmingly predominate human-feeding anopheline collected; whereas in the current study this species was relatively uncommon during the intervention trial. The range of ecologies (coastal plains to upland forested hills) varied greatly across the 12 clusters used for entomology collections in this trial compared to that of the earlier Sumba study where collections were confined to only 4 adjoining clusters having similar coastal environments. This spatial variability in ecology contributed to a broader range of species diversity. We report 19 species/group species identified), each species with different bionomic and behavioral characteristics (e.g., biting habits, host preferences). Perhaps most important, the efficacy of an intervention is related to epidemiological outcomes (reduced risk of infection); HLC outcomes reported from the current study were inconclusive, but nevertheless showed impact against malaria.

Insecticide susceptibility monitoring was integrated into the study to characterize the wild-type anopheline populations to estimate PE against resistant vector populations, if resistance was expressed, and monitor changes in susceptibility due to continuous exposure to transfluthrin. Our data indicates that continual use of transfluthrin as a spatial repellent during a consecutive 24-mo period did not result in a change in phenotypic response to permethrin. Although we are confident in the findings presented, there were limitations in sampling from multiple sites and handling numerous species during pre-, within, and post-intervention periods. This may have compromised the study's ability to obtain a more robust and definitive profile of susceptibility background and detection of any shift in phenotypic (and molecular) frequencies.

677 The third 'lesson-learned' from the current study relates to AE and SAE monitoring.
678 Reports of intervention safety in this study should take into account possible limitations of the
679 data collection. The DSMB was provided with clinic attendance data from January 2015 to
680 December 2018, for upper respiratory infection (URI), pneumonia, and malaria, as classified by
681 month, health center, and village within health center coverage. Although not gathered as part of
682 the study, the DSMB was keenly interested in these data because of the surprisingly low number
683 of illnesses/deaths reported from the study population during the 24-month intervention period.
684 For some periods, particularly for malaria infection, the case data were missing or the health
685 center totals were not available at the village level. Of the 13 villages represented in the dataset,
686 from which study clusters were formed, all but four comprised clusters (or parts of clusters) from
687 both study intervention arms (i.e., allocated active or placebo); therefore, it was not possible to
688 infer the allocation status of the corresponding cases. For this reason, the DSMB was unable to
689 make a reliable assessment of any possible association between active intervention and clinic
690 attendance for those reported health conditions. The respiratory illnesses in the clinic data are
691 more reflective of the magnitude of numbers of cases one would expect from this population;
692 however, the DSMB was again unable to parse them into test and control clusters due to reasons
693 stated above, and therefore the data was of little use for monitoring purposes. The number of
694 SAEs reported, a total of six, is well below the expected in a study population of this size. The
695 WHO estimates the crude death rate in Indonesia to be approximately 6.2 per thousand per
696 year.[56] Based on this, for a population of 1,296 children enrolled (protocol sample size), the
697 probability of having zero deaths in a year is less than one in 1,000. Although open
698 commemoration of deaths is commonly practiced in the study area, it seems more likely deaths
699 were not completely reported/recorded as SAEs.

700 Overall, the point to apply for future spatial repellent trials (and perhaps other trials of
701 new vector control interventions) is to improve the mechanism for capturing and communicating
702 AEs and SAEs before the initiation of the study to better ensure reliable reporting and regular
703 monitoring for unusual numbers of complaints. If these studies are regarded as a clinical trial
704 with a placebo arm that requires comparative AE and SAE data, the scale could cause failure in
705 safety assessment simply on the mass of data, however imperfectly collected. Any safety signal
706 detected would most likely be due to bias in reporting and/or collection bias and unrelated with
707 the investigational intervention. Trials evaluating a spatial repellent intervention with a registered
708 active ingredient (i.e., a chemical meeting regulatory approvals for acceptable levels of human
709 risk) such as transfluthrin, could focus on a small number of complaints that might be expected
710 due to inhalation (i.e., volatilization) and develop a monitoring scheme that collects consistent
711 data across the study population. Clinic-based complaints of respiratory illness such as
712 pneumonia and asthma might be possible, but the variability in their method of collection (clinic
713 or survey) will likely be highly dependent on study site infrastructure.

714 In conclusion, while more evidence will be required to determine whether spatial
715 repellents can serve as a viable malaria control intervention, both the primary and secondary
716 results of this Sumba Island trial have generated valuable data and observations that can
717 contribute to the overall assessment and improvement of testing protocols of a spatial repellent
718 intervention class. The VCAG has recommended that data from at least one additional trial
719 evaluating the spatial repellent be generated,[57] and once available, the panel will be able to assess
720 the available evidence for judging public health value. If the crude estimate of PE shown here,
721 near 30%, is replicated in future statistically robust cluster-randomized trials, the intervention
722 prototype evaluated in this RCT would approximate the benefit associated with LLINs.[58] Perhaps

723 just as important, the difference in the overall (total new) infection rate between transfluthrin-
724 active and placebo-control, i.e., the number of cases averted, indicates 361 expected cases per
725 1000 persons per year (0.361*1000*1) without the spatial repellent and 152 less cases expected
726 when using the active intervention ((0.361-0.209)*1000*1). The cost-savings of averting these
727 152 less cases per 1000 person-years is an important consideration for health-systems
728 strengthening. These results have encouraged further and substantial investment to validate
729 spatial repellent efficacy through larger RCTs, including an investigation of possible vector
730 diversionary effects on human health (i.e., greater than expected malaria incidence in households
731 near intervention not receiving active product), and evaluation of the optimal delivery systems
732 for humanitarian assistance use-case scenarios.[59]
733

734 **Acknowledgments:** We extend sincere appreciation to DSMB members: Dennis Shanks, Chris
735 Drakeley, and Neal Alexander for assurances on data integrity and safety assessments. We also
736 express our gratitude to fhi360 partners Kathy Bowerman, Ahmed Goolam and Zen Hafy for
737 trial oversight and monitoring of protocol compliance. We thank the WHO VCAG for their
738 comments from recurrent project data assessments. We are grateful for the tireless efforts of
739 Wirda Damanik, study administrator at the Eijkman Institute for Molecular Biology in Jakarta,
740 and Marianne Kent, Program Coordinator at the University of Notre Dame, for their expert
741 administrative, logistical, and financial management support of this endeavor. We thank Julie
742 Neidbalski, Katie Cybulski, Diane Lovin, Joanne Cunningham, Jenna Davidson, and Allison
743 Hendershot at the University of Notre Dame for their contribution to human blood and mosquito
744 sample quality control processing as well as David Pettifor of the University of Notre Dame
745 Center for Research Computing for assisting with central database development and data

verification. We gratefully thank the residents in the study area for their time and patience participating in this trial. Special gratitude is extended to the Southwest and West Sumba Districts Health Department for their kind support, the parasitology and entomology teams, local field workers, data entry clerks, and the numerous local volunteers for their long-serving dedication to quality of data and meeting the project objectives.

Financial support: This study was funded by a substantial award from the Bill and Melinda Gates Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). We express our gratitude to the Foundation for their long-term generosity and support of spatial repellent product evaluation and development, especially Kate Aultman, Dan Strickman and Alan Magill. We are also deeply grateful to SC Johnson for its financial support. The company provided integral industry and product expertise including the development, manufacturing, delivery and shipment of the intervention (active and placebo) used in the study. Additionally, SC Johnson provided expertise in ensuring intervention quality, storage, application and disposal assurances throughout the trial.

Disclaimer: The contents are the responsibility of the authors.

765 REFERENCES

766 1. Kennedy JS, 1947. The Excitant and Repellent Effects on Mosquitos of Sub-lethal Contacts
767 with DDT. *Bull Entomol Res 37:* 593-607.

768 2. Muirhead-Thomson RC, 1951. Mosquito Behaviour in relation to Malaria Transmission and
769 Control in the Tropics. London: Edward Arnold & Co., 219.

770 3. De Zulueta J, Cullen JR, Smith A, 1963. Deterrent Effect of Insecticides on Malaria Vectors
771 . *Nature 200:* 860-862.

772 4. Dethier VG, Browne BL, Smith CN, 1960. The Designation of Chemicals in Terms of the
773 Responses They Elicit from Insects. *J Econ Entomol 53:* 134-136.

774 5. Miller JR, Siegert PY, Amimo FA, Walker ED, 2009. Designation of Chemicals in Terms of
775 the Locomotor Responses they Elicit from Insects: an Update of Dethier et al. (1960). *J Econ*
776 *Entomol 102:* 2056-2060.

777 6. Roberts DR, Alecrim WD, Hshieh P, Grieco JP, Bangs M, Andre RG, Chareonviriphap T,
778 2000. A Probability Model of Vector Behavior: Effects of DDT Repellency, Irritancy, and
779 Toxicity in Malaria Control. *J Vector Ecol 25:* 48-61.

780 7. WHO Pesticide Evaluation Scheme, 2013. Guidelines for Efficacy Testing of Spatial
781 Repellents. Geneva: World Health Organization.

782 8. Grieco JP, Achee NL, Sardelis MR, Chauhan KR, Roberts DR, 2005. A Novel High-
783 Throughput Screening System to Evaluate the Behavioral Response of Adult Mosquitoes to
784 Chemicals. *J Am Mosq Control Assoc 21:* 404-411.

785 9. Achee NL, Sardelis MR, Dusfour I, Chauhan KR, Grieco JP, 2009. Characterization of Spatial
786 Repellent, Contact Irritant, and Toxicant Chemical Actions of Standard Vector Control
787 Compounds. *J Am Mosq Control Assoc 25:* 156-167.

788 10. Ogoma SB, Ngonyani H, Simfukwe ET, Mseka A, Moore J, Maia MF, Moore SJ, Lorenz
789 LM, 2014. The Mode of Action of Spatial Repellents and Their Impact on Vectorial Capacity of
790 *Anopheles gambiae sensu stricto*. *PLoS ONE 9:* e110433.

791 11. Ogoma SB, et al, 2014. An Experimental Hut Study to Quantify the Effect of DDT and
792 Airborne Pyrethroids on Entomological Parameters of Malaria Transmission. *Malar J 13:* 131.

793 12. Grieco JP, Achee NL, Chareonviriyaphap T, Suwonkerd W, Chauhan K, Sardelis MR,
794 Roberts DR, 2007. A New Classification System for the Actions of IRS Chemicals Traditionally
795 Used For Malaria Control. *PLoS One 2:* e716.

796 13. U.S EPA Office of Pesticide Programs, 2018. Conventional New Chemical Registration
797 Decisions - Completed FY 2018.

798 14. Norris E, Coats J, 2017. Current and Future Repellent Technologies: The Potential of Spatial
799 Repellents and Their Place in Mosquito-Borne Disease Control. *International Journal of*
800 *Environmental Research and Public Health 14:* 124.

801 15. Debboun M, Frances SP, Strickman D, 2006. Insect Repellents: Principles, Methods, and
802 Uses. Boca Raton, FL: CRC Press, 495.

803 16. WHO, 2017. The Evaluation Process for Vector Control Products. *WHO.* Geneva: World
804 Health Organization.

805 17. Maia MF, Kliner M, Richardson M, Lengeler C, Moore SJ, 2018. Mosquito Repellents for
806 Malaria Prevention. Available at: /CD011595/INFECTN_mosquito-repellents-malaria-
807 prevention. Accessed Oct 24, 2019.

808 18. Hill N, Zhou HN, Wang P, Guo X, Carneiro I, Moore SJ, 2014. A Household Randomized,
809 Controlled Trial of the Efficacy of 0.03% Transfluthrin Coils Alone and in Combination with
810 Long-Lasting Insecticidal Nets on the Incidence of *Plasmodium falciparum* and *Plasmodium*
811 *vivax* Malaria in Western Yunnan Province, China. *Malar J 13:* 208.

812 19. Syafruddin D, et al, 2014. Impact of a Spatial Repellent on Malaria Incidence in Two
813 Villages in Sumba, Indonesia. *Am J Trop Med Hyg 91:* 1079-1087.

814 20. WHO-Department of Control of Neglected Tropical Diseases, 2017. How to Design Vector
815 Control Efficacy Trials. Guidance on Phase III Vector Control Field Trial Design. *WHO.*
816 Geneva: World Health Organization. 62.

817 21. Ogoma SB, Moore SJ, Maia MF, 2012. A Systematic Review of Mosquito Coils and Passive
818 Emanators: Defining Recommendations for Spatial Repellency Testing Methodologies. *Parasit*
819 *Vectors 5:* 287.

820 22. Achee NL, Grieco JP, 2012. Is It Time to Formally Recognize Spatial Repellency for Disease
821 Prevention? *Outlooks on Pest Management 23:* 283-286.

822 23. Achee NL, et al, 2012. Spatial Repellents: from Discovery and Development to Evidence-
823 Based Validation. *Malar J 11:* 164.

824 24. Hemingway J, Shretta R, Wells TNC, Bell D, Djimdé AA, Achee N, Qi G, 2016. Tools and
825 Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand
826 Convergence in Malaria? *PLoS Biol 14:* e1002380.

827 25. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research,
828 2018. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). *FDA.* Silver Spring,
829 MD: US Food and Drug Administration.

830 26. OECD, OECD Series on Principles of Good Laboratory Practice (GLP) and Compliance
831 Monitoring. Available at:

832 http://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpa
833 ndcompliancemonitoring.htm.

834 27. Badan Pusat Statistik, 2010 Population Census - Indonesia. Available at:
835 http://sp2010.bps.go.id/. Accessed Jul 10, 2019.

836 28. Elyazar IRF, Sinka ME, Gething PW, Tarmidzi SN, Surya A, Kusriastuti R, Winarno, Baird
837 JK, Hay SI, Bangs MJ, 2013. The Distribution and Bionomics of Anopheles Malaria Vector
838 Mosquitoes in Indonesia. D. Rollinson, ed. Advances in Parasitology. Amsterdam: Elsevier Ltd.,
839 173-266.

840 29. Barbara KA, Sukowati S, Rusmiarto S, Susapto D, Bangs MJ, Kinzer MH, 2011. Survey of
841 *Anopheles* Mosquitoes (Diptera:Culicidae) in West Sumba District, Indonesia. *Southeast Asian J*
842 *Trop Med Public Health 42:* 71-82.

843 30. Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, Bejon P, Leach A, 2011.
844 Statistical Methodology for the Evaluation of Vaccine Efficacy in a Phase III Multi-centre Trial
845 of the RTS, S/AS01 Malaria Vaccine in African Children. *Malar J 10:* 222.

846 31. LaRue N, et al, 2014. Comparison of Quantitative and Qualitative Tests for Glucose-6-
847 Phosphate Dehydrogenase Deficiency. *Am J Trop Med Hyg 91:* 854-861.

848 32. Bernard Nkrumah, Samuel Blay Nguah, Nimako Sarpong, Denise Dekker, Ali Idriss, Juergen
849 May and Yaw Adu-Sarkodie, 2011. Hemoglobin Estimation by the HemoCue® Portable
850 Hemoglobin Photometer in a Resource Poor Setting. *BMC Clinical Pathology 11:*.

851 33. WHO Specifications and Evaluations for Public Health Pesticides, 2016. Transfluthrin.
852 *World Health Organization.* Geneva: WHO.

853 34. United States Environmental Protection Agency, 2018. Registration Decision for the New
854 Active Ingredient, Transfluthrin. Washington, DC: US EPA.

855 35. Echeverry DF, et al, 2016. Human Malaria Diagnosis Using a Single-step Direct-PCR Based
856 on the *Plasmodium* cytochrome oxidase III gene. *Malar J 15:* 128.

857 36. World Health Organization & UNICEF/UNDP/World Bank/WHO Special Programme for
858 Research and Training in Tropical Diseases, 2015. Microscopy for the Detection, Identification
859 and Quantification of Malaria Parasites on Stained Thick and Thin Blood Films in Research
860 Settings. *World Health Organization.* 33.

861 37. O'Connors CT, Soepanto A, 1979. Kunci kunci bergambar untuk Anopheles betina dari
862 Indonesia. Translated and revised by Atmosoedjono S, Bangs, MJ, 1989. Illustrated key to the
863 *Anopheles* of Indonesia. 1989. Jakarta, Indonesia: The Ministry of Health. 1-40.

864 38. Detinova TS, 1962. Age-grouping Methods in Diptera of Medical Importance with Special
865 Reference to some Vectors of Malaria. *Monogr Ser World Health Organ 47:* 13-191.

866 39. Lobo NF, et al, 2015. Unexpected Diversity of *Anopheles* Species in Eastern Zambia:
867 Implications for Evaluating Vector Behavior and Interventions using Molecular Tools. *Sci Rep*
868 *5:* 17952.

869 40. St Laurent B, et al, 2016. Behaviour and Molecular Identification of *Anopheles* Malaria
870 Vectors in Jayapura District, Papua Province, Indonesia. *Malar J 15:* 192.

871 41. Echeverry DF, et al, 2017. Fast and Robust Single PCR for *Plasmodium* sporozoite Detection
872 in Mosquitoes using the Cytochrome Oxidase I Gene. *Malar J 16:* 230.

873 42. Beier JC, 2002. Vector Incrimination and Entomological Inoculation Rates. *Methods Mol*
874 *Med 72:* 3-11.

875 43. WHO, 2016. Test Procedures for Insecticide Resistance Monitoring in Malaria Vector
876 Mosquitoes (Second edition). Geneva: World Health Organization.

877 44. Center for Disease Control and Prevention, 2010. Guideline for Evaluating Insecticide
878 Resistance in Vectors Using the CDC Bottle Bioassay. Atlanta: The Centers.

879 45. John D. Kalbfleisch, Ross L. Prentice, 2002. The Statistical Analysis of Failure Time Data.
880 John Wiley and Sons, 462.

881 46. Paul D. Allison, 1982. Discrete-Time Methods for the Analysis of Event Histories.
882 *Sociological Methodology 13:* 61-98.

883 47. David Collett, 2002. Modelling Binary Data. London: Chapman and Hall/CRC, 408.

884 48. Redmond, C. and Colton, T., ed., 2001. Biostatistics in Clinical Trials. John Wiley & Sons.

885 49. Baird JK, Bangs MJ, Maguire JD, Barcus MJ, 2002. Epidemiological Measures of Risk of
886 Malaria. *Methods Mol Med 72:* 13-22.

887 50. World Health Organization, 2018. World Malaria Report 2018. *WHO.* World Health
888 Organization.

889 51. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD, 2009.
890 Adaptive Designs for Randomized Trials in Public Health. *Annu Rev Public Health 30:* 1-25.

891 52. Shein-Chung Chow, Mark Chang, 2011. Adaptive Design Methods in Clinical Trials.
892 London: Chapman and Hall/CRC Biostatistics Series, 375.

893 53. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ,
894 2008. GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of
895 Recommendations. *BMJ 336:* 924-926.

896 54. Frieden TR, 2017. Evidence for Health Decision Making - Beyond Randomized, Controlled
897 Trials. *N Engl J Med 377:* 465-475.

898 55. Wilson AL, Boelaert M, Kleinschmidt I, Pinder M, Scott TW, Tusting LS, Lindsay SW,
899 2015. Evidence-based Vector Control? Improving the Quality of Vector Control Trials. *Trends*
900 *Parasitol 31:* 380-390.

901 56. WHO-Global Health Observatory Data Repository, 2015. Crude Birth and Death Rate
902 Data by Country. Available at: http://apps.who.int/gho/data/view.main.CBDR2040. Accessed
903 07/08/2019.

904 57. VCAG, Vector Control Advisory Group. Available at: http://www.who.int/vector-
905 control/vcag/en/. Accessed Jul 10, 2019.

906 58. Lengeler C, 2004. Insecticide-treated Bed Nets and Curtains for Preventing Malaria.
907 *Cochrane Database Syst Rev* CD000363.

908 59. Unitaid, Innovative Repellents for Disease-carrying Mosquitoes. Available at:
909 https://unitaid.org/project/innovative-repellents-for-disease-carrying-mosquitoes/. Accessed Jul
910 10, 2019.

911

TABLES

Table 1. Malaria infection prevalence data from 10 months before randomization in the 13 villages from which study clusters were delineated on Sumba Island.

Village	Number of samples	Number of malaria infections	Slide Positive (%)
Matakapore	806	110	13.65
Manutoghi	622	217	34.88
Waimakaha	621	149	23.99
Wailangira	857	52	6.07
Waikarara	1,420	63	4.44
Panenggo Ede	610	15	2.46
Waimaringi	649	67	10.32
Tana Mete	810	81	10.00
Kahale	903	202	22.37
Rada Malando	402	150	37.31
Karang Indah	523	195	37.28
Gaura	1,297	165	12.70
Weetana	1,129	163	14.40

Table 2. Summary baseline covariates for both spatial repellent (SR) and placebo treatment arms for the primary analysis.

Individual level		
	SR (n = 665)	**Placebo (n = 667)**
Age in months (mean ± SD, (min, max))	34.0 ± 15.1 (6, 59)	34.2 ± 14.8 (6, 59)
Gender (% male subjects)	54.1%	51.1%
Household level		
	SR (n = 665)	**Placebo (n = 667)**
House wall type (wood %)	91.6%	94.0%
Open eaves (yes %)	98.0%	99.6%
No. of doors (mean ± SD, (min, max))	2.06 ± 0.38 (1, 4)	2.06 ± 0.30 (0, 4)
Cluster level		
	SR (n = 12)	**Placebo (n = 12)**
Cluster population (mean ± SD, (min, max))	694.3 ± 59.2 (624, 820)	730.8 ± 129.0 (616,1117)
Baseline incidence rate per person-year (mean ± SD, (min, max))	0.096 ± 0.115 (0, 0.426)	0.089 ± 0.088 (0, 0.265)
Baseline overall (total new) infection incidence per person-year (mean ± SD, (min, max))	0.094 ± 0.111 (0, 0.412)	0.089 ± 0.087 (0, 0.261)

Table 3. Summary first-time and overall (total new) malaria incidence during study.

	First-time infection			Overall (total new) infections		
	All clusters	**Subgroup 1[#]**	**Subgroup 2[*]**	**All clusters**	**Subgroup 1[#]**	**Subgroup 2[*]**
	SR : Placebo					
No. of clusters	12:12	10:9	6:6	12:12	10:9	6:6
No. of households	665 : 667	557 : 500	335 : 335	665 : 667	557 : 500	335 : 335
No. of infections	134 : 164	130 : 158	93 : 140	253 : 439	249 : 433	196 : 408
Person years	1079 : 1032	873 : 722	506 : 444	1216 : 1216	1015 : 909	609 : 607
Incidence rate (per person-year)	0.124 : 0.159	0.149 : 0.219	0.184 : 0.315	0.208 : 0.361	0.245 : 0.476	0.322 : 0.672
Hazard Ratio (90% CI)	0.723 (0.431,1.213)	0.64 (0.299, 1.367)	0.447 (0.302, 0.664)	0.687 (0.426,1.108)	0.591 (0.382, 0.914)	0.344 (0.233, 0.508)
PE (%) (90% CI)	27.7 (-21.3, 56.9)	33.3 (-7.8, 58.7)	55.3 (33.6, 69.9)	31.3 (-10.8, 57.4)	40.9 (8.61, 61.8)	65.6 (49.2, 76.7)
1-sided *p*-value	0.151	0.083	0.0004	0.098	0.0236	<0.0001

[#] Subgroup 1: clusters with non-zero incidence during intervention
[*] Subgroup 2: clusters with entomology data collected (moderate-to-high risk of infection)

Table 4: Intervention effect on anopheline mosquito landing rates by collection location.

Location[1]	**SR (mean ± SD)** [2]	**Placebo (mean ± SD)**	**% Change (95% CI) SR vs. Placebo**	***p*-value**
Indoor	3.14 ± 5.84	3.97 ± 8.73	-16.4 (-75.2, 182.7)	0.774
Outdoor	3.54 ± 7.13	3.93 ± 8.64	-11.3 (-73.7, 199.4)	0.847

[1] Position at each human landing catch (HLC) sentinel house where sample was captured (indoor = near center of house; outdoor = on verandah ~1m from edge of exterior wall.
[2] Human landing rate based on 12-hour collection per person.

Table 5. Frequency of anopheline (all species) sporozoite infection status for both spatial repellent (SR) and placebo treatment arms.

Treatment Allocation	Pf[1]	Pv[2]	Indeterminate[3]	Non-infected	Sporozoite Positivity Rate[4]
Baseline					
SR	12	9	0	4706	0.44%
Placebo	12	9	0	6244	0.34%
Intervention					
SR	3	8	0	8130	0.14%
Placebo	6	1	1	9615	0.07%

[1]Pf = *Plasmodium falciparum*
[2]Pv= *Plasmodium vivax*
[3]Indeterminate defined as *Plasmodium* positive sample but parasite species not identifiable
[4]Sporozoite positivity rate = [(Pf + Pv) / (Pf + Pv + Indeterminate + non-infected)] x 100%

Table 6. Spatial repellent (SR) intervention effect on parity and nulliparity rates (all anopheline species).

	HLC Location[1]	SR (mean ± SD)[2]	Placebo (mean ± SD)	% Change (95% CI) SR vs. Placebo	2-sided *p*-value
Parous	Indoor (n=5,784)	0.41 ± 0.44 (n=2,537)	0.41 ± 0.45 (n=3,247)	-10.2 (-62.1, 113.2)	0.808
	Outdoor (n=6,193)	0.40 ± 0.44 (n=2,907)	0.43 ± 0.45 (n=3,286)	-25.9 (-68.8, 75.6)	0.495
Nulliparous	Indoor (n=1,873)	0.16 ± 0.29 (n=994)	0.12 ± 0.26 (n=879)	58.3 (-37.0, 298.0)	0.329
	Outdoor (n=1,978)	0.17 ± 0.30 (n=1,126)	0.11 ± 0.25 (n=852)	54.9 (-37.6, 284.3)	0.346

[1] Position of collector conducting human landing catch (HLC) (indoor = near center of house; outdoor = on house verandah ~1m from edge of exterior wall).
[2] Mean and SD are descriptive statistics; and % change was obtained from fitting negative binomial models.

FIGURES

Figure 1. Study site areas in Southwest and West Sumba districts located in Kodi, Kodi Bangedo and Lamboya sub-districts of Sumba Island, Nusa Tenggara Timur Province (eastern Lesser Sunda islands), Indonesia (map not to scale).



Figure 2. Traditional Sumba house structure (A) raised ~1m above ground and averaging ~70 m^3 in size with thatch roof, bamboo floors and walls (B), which offer minimal protection from mosquito entry.

Figure 3. Location of 24 study clusters in West and Southwest districts, Sumba. Clusters were selected for enrolling the incidence cohort, each consisted of ca. 100 households with an average distance of 500m between clusters. A total of 48 sentinel houses from 12 clusters were selected for routine entomological human landing catch (HLC).



Figure 4. Flowchart of enrollment of study volunteers.



Figure 5: Cumulative incidence of time to first-infection for each of the 24 study clusters (spatial repellent (SR) intervention and placebo treatment arm).



Figure 6. Mean (+ SD) cumulative biweekly indoor (A) and outdoor (B) anopheline human landing catch (HLC) averaged over 20 to 24 households per treatment arm - spatial repellent (SR) intervention and placebo, respectively.